Business Context and Reporting Period
This Form 8-K, dated October 4, 2024, reports on Bellevue Life Sciences Acquisition Corp. (BLAC), a Special Purpose Acquisition Company (SPAC). The filing details a material definitive agreement entered into to secure capital for a pending business combination with OSR Holdings Co., Ltd., a Korean corporation. The filing does not contain historical financial performance data for a specific reporting period as it is a current report on a specific transaction.
Key Financial Metrics and Transaction Details
The primary financial event is a Private Investment in Public Equity (PIPE) transaction. Key terms include:
- Investment Amount: $20,000,000 aggregate purchase price.
- Instrument: 222,222 shares of Series A Preferred Stock.
- Price Per Share: $90.00 (Series A Original Issue Price).
- Dividend Rate: 5% per annum accrual (payable if declared).
- Conversion Price: Initially $9.00 per share of common stock.
- Redemption Terms: Company may redeem after one year at 7.0% accrued dividend rate; holders may demand redemption after three years.
The filing does not provide current revenue, profit, cash flow, or debt metrics for the registrant or OSR Holdings.
Material Changes and Transaction Purpose
The material change is the execution of a Subscription Agreement with Toonon Partners Co., Ltd. The capital raised is designated for use by the Company following the closing of the business combination with OSR Holdings. The transaction is contingent upon the consummation of the business combination and the filing of a Certificate of Designations with the Delaware Secretary of State.
Outlook, Risks, and Contingencies
Outlook and Conditions: The transaction is subject to customary closing conditions, including the successful completion of the business combination. A registration rights agreement will be executed to register the common stock issuable upon conversion of the preferred shares.
Risks and Contingencies: The filing highlights significant risks that could prevent the transaction or alter future performance, including:
- Failure to obtain stockholder approval for the business combination.
- Termination of the definitive agreement due to unforeseen events.
- Inability to maintain Nasdaq listing post-combination.
- Disruption of OSR Holdings' operations during the combination process.
- Global health disruptions (e.g., pandemics) affecting operations.
- Competition and market demand for OSR Holdings' technologies.
Management explicitly states that forward-looking statements involve uncertainties and should not be relied upon as predictions of future events.
Investor Verification Checklist
- Verify the status of the Form S-4 Registration Statement and the definitive proxy statement regarding the OSR Holdings business combination.
- Confirm the filing of the Certificate of Designations for the Series A Preferred Stock with the Delaware Secretary of State.
- Review the "Risk Factors" section in the Form S-4 and the most recent Form 10-K for detailed risks associated with OSR Holdings.
- Monitor the timeline for the special meeting of stockholders to vote on the business combination.
- Assess the financial health and operational status of OSR Holdings, as this filing contains no financial data for the target company.